Any carcinogenic tissue formation Oral malignancy refers to cancer in the mouth. Malignant oral cancer development is a serious medical problem that affects people all over the world.

Despite the fact that a variety of tumors can be identified inside the oral depression, the majority of the time (90 percent) the tumor is an oral Skin cancer, also known as squamous cell carcinoma (SCC), is a kind of cancer that affects the skin (OSCC). Malignant neoplasms are a leading cause of worldwide fear, illness, and death. The World Health Organization's (WHO) International Classification of Diseases (ICD) coding system is used by most international databases, with the ninth iteration accounting for the majority of data already available (ICD-9). Squamous cell carcinoma is the most common type of oral cancer that looks the same under a magnifying lens. The palate, the floor of the mouth, the cheek lining, the gingiva (gums), and the gingiva (gums) can all be impacted. Squamous cell carcinoma, which develops in the tissues that line the mouth and lips, is the most well-known oral cancer. Oral or mouth malignant growth most usually affects the tissue of the lips and tongue. It could begin as a serious injury to any of the oral tissues, spread from a faraway source, or be boosted by a neighboring anatomic feature, such as the nasal pit or maxillary sinus. Oral squamous cell carcinomas affect 90 to 95 percent of these patients (OSCCs). Every year, nearly 300,000 new instances of oral cancer are investigated around the world. The TNM characterization framework (the standard foundation for treatment decisions, which is based on histology tumor grade) has been shown to be a poor predictor of visibility. The goal of this section is to rapidly go through how tumor markers can be used to anticipate how OSCCs will behave in the natural world. Identifying novel indications of OSCC has been a key research focus in recent decades, with the goal of better predicting tumor behavior and clinical outcomes. Oral squamous cell carcinoma (OSCC) and salivary organ disease are the sixth and sixth most common cancers, respectively [1].

According to many studies, universal community screening There are a lot of false positive referrals, and it has little impact on overall survival. [2-4]. As a result, successful screening will require a full understanding of the cause, pathophysiology, and behavior of premalignant and serious oral injuries, as well as a method for identifying people at high risk of developing cancer (Table 1.1).

Table 1.1: Parts of an Oral Cancer Screening Examination.

Oral illness classification is necessary for determining the best treatment. Tumors are now organized using the TNM order framework (Table 1.2). One of the most important prognostic indicators is the stage of the tumor at the time of diagnosis. Early-stage infection (stages 3 or 4) has a survival rate of approximately 80%, while advanced-stage infection (stages 3 or 4) has a survival rate of only 21%. 19 Staging evaluations look at the severity of local, territorial, and inaccessible illness, as well as therapeutic data on a patient's practical and execution state, which helps with treatment management.

As A Result of The Cancer Treatment, There Are Several Side Effects.

Medical procedure, irradiation (radiation treatment), chemotherapy, some of the strategies utilized in disease management include hormone therapy and natural therapies. All of these procedures have the potential to cause a variety of oral problems, some of which are some are more serious (for example chemotherapy, head, and neck radiotherapy). To be sure, the National Cancer Institute estimates that 10% of patients receiving adjuvant chemotherapy, 40% of patients receiving essential chemotherapy, 80% of patients receiving myeloablative chemotherapy (for example, during hematopoietic foundational microorganism transplantation), and all patients receiving head and neck radiotherapy will develop oral complications [6].

The most common oral adverse effects of traditional chemotherapy are listed in (Table 1.3.) As indicated in (Table 1.4), radiation-induced oral problems are almost always the outcome of a treatment's local influence. Surprisingly, oral symptoms are also linked to the novel "focused on" treatments (Tables 1.5 and 1.6) [7].

Table 1.2: TNM Oral Cancer Staging.

Springer-Verlag provided the data for this article [5].

Table 1.3: Chemotherapy-related oral problems [6].

Table 1.4: Oral problems of head and neck radiation therapy [6].

Table 1.5: Oral side effects of certain new chemotherapeutic drugs [7].

The term 'ulcer' refers to a full-thickness epithelium loss with the insertion of hidden connective tissue [8]. Ulceration can occur for a variety of reasons in patients with malignant growth, including explicit causes (such as those discovered during the malignant growth/disease therapy) and non-explicit causes (such as those not identified during the malignant growth/disease treatment) (for example identified with other factors). Table1.6 [9] lists the most often recognized causes of mouth ulcers among the general audience. The evaluation of oral ulcers requires essential clinical skills (such as collecting a history and performing an examination) as well as the application of appropriate inquiry (such as microbiological tests and tissue analysis). Various ulcers that are rigorous in nature also advocate medications, mucocutaneous illness, hematological disarrays, or gastrointestinal malady (the phrase 'disintegration' is used to describe a midway thickness loss of epithelium.).

Table 1.6: Oral side effects of new biological agents [7].

1-EGFR

ErbB1 (human epidermal development factor receptor 1), ErbB2 (HER 2), ErbB3 (HER3), and ErbB4 (HER4) are tyrosine kinases that belong to the ErbB1 (human epidermal development factor receptor 1), ErbB2 (HER 2), ErbB3 (HER3), and ErbB4 (HER4) families [11].EGF, also known as transforming growth factor (TGF), stimulates the activity of Ras/Raf/mitogen-initiated kinase protein (MAPK), phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT), mTOR, Janus tyrosine kinase (JAK), signal transducers, and transcription active proteins. Overexpression of EGFR has been linked to a cutting-edge clinical stage and a poor prognosis in practically every case of head and neck cancer [13]. Overexpression of HER2 has also been linked to nodal metastases and a poor prognosis for Squamous cell cancer (SCC) of the head and neck [14]. Gefitinib and erlotinib, EGFR tyrosine kinase inhibitors, are relatively tiny molecules [12]. Gefitinib and erlotinib are small-molecule EGFR tyrosine kinase inhibitors, and cetuximab is an EGFR monoclonal immunizer. It's possible that an EGFR-targeted atomic therapy for OSCC may be beneficial.

2-NFκB

In the context of intertwined inflammation and the invulnerable response [12, 15], nuclear factor-kappa B (NFκB) is a widespread atomic interpretation. In its dormant stage, NFκB is linked to members of the NFκB inhibitor (IB) family and is found in the cytoplasm. Activated NFκB translocate to the core when IκB is phosphorylated, ubiquitinated, or degraded, and governs the declaration of target features [16].NFκB promotes lymphatic metastasis, assault, and angiogenesis in OSCC [17–19]. In addition, the expression of NFB in OSCC has been associated to protection against chemoradiation treatment [20].

3-PI3K - AKT

PI3K/AKT promotes malignant development cell creation and multiplication as a downstream target of EGFR [21]. The p85 and p110 subunits of PI3K form a heterodimeric kinase (PI3KCA). In about 10% of head and neck SCC, tensin homolog (PTEN) has been discovered [22, 23]. The activation of EGFR-dependent PI3K/AKT in OSCC is common and has been associated to radiation blockage [21]. In head and neck malignancies, including OSCC, one of the most important signaling pathways is PI3K-PTEN-AKT.

4-Cyclin D1

Cyclin D1 is a protein that regulates the cell cycle from G1 to S. CDK4 (calcium-subordinate kinase 4) is involved [24]. In 25–70% of OSCC cases, Overexpression of cyclin D1 is associated with nodal metastases and poor prognosis. prognostic marker [25, 26]. An increase in ERK1/2, an extracellular signal-regulated kinase, boosts cyclin D1 articulation. according to a recent study employing OSCC cells [26]. Cyclin D1 also has a role in cisplatin resistance by inhibiting apoptosis and activating NFB [27]. After E6 and E7 downregulate p53 and pRb, respectively, cyclin D1 mobility is reduced in HPV-related oral cancer [15].

5-STAT

The cytoplasmic interpretation factors [12, 15] are members of the STAT family of proteins. JAK, IL-6, EGF, PDGF, VEGF, and JAK/IL-6 other proteins are activated in a few malignancies [28]. According to an ongoing investigation [29], inactivating STAT3 diminishes the articulation of Hypoxia-inducible factor 1 (HIF-1) is a protein that limits cell growth. development, and raises the radio sensitivity OSCC cells are a kind of cancer cell. Immunohistochemistry investigations involving human OSCC cases, STAT3 articulation is linked to poor visibility and can be found in premalignant sores. The co-articulation of STAT3 and c-Met helps the OSCC moving along.

6- P53

On chromosome 17p13.1, P53 is found. In HPV-positive OSCC, P53 is inactivated by a connection with E6, which causes P53 to be ubiquitinated and proteolyzed [12, 31]. Hypoxia, P53 articulation is increased by p14 ARF initiation and DNA double-strand breaks [32, 33]. The cell cycle, cell separation, DNA fixing, and apoptosis are all influenced by P53 [12].

7-Bcl-2, Bcl-XL, Bax, and Bak

Overexpression of Bcl-2 in OSCC has been recommended as a useful predictor of poor prognosis [36]. The overexpression of Bcl - XL and wild-type p53 in head and neck SCC cells has been linked to cisplatin blocking [37]. Despite the fact that Bax and Bak are proapoptotic proteins, their high articulation has been connected to a bad prognosis in OSCC [38,39].

Insufficient Bax articulation, on the other hand, was linked to poor guessing in another study [40]. Furthermore, reduced levels of In OSCC, Bax and Bak have been associated to hypoxia-induced apoptosis [41].

8- MicroRNAs

MicroRNAs (miRNAs) are 18–25 nucleotide noncoding RNAs that regulate the quality of mRNA by binding to its 3′-untranslated region (UTR). [42]. Essential miRNAs (pri-miRNAs) are converted to precursor miRNAs (pre-miRNAs) by DiGeorge, a cofactor of RNase Drosha (DCRG8). The pre-miRNAs are transported to the cytoplasm by Exportin-5, where they are transformed into miRNAs by RNase Dicer. When incorporated into the RNA-initiated hushing complex (RISC), increase miRNAs obstruct target quality mRNA articulation [43–46]. The work of a few miRNAs has been condensed in OSCC [44, 45].

9-Upregulation of miRNAs in OSCC

Increased miR-222 articulation lowers manganese superoxide dismutase 2 (SOD2) articulation and hence inhibits cell invasion [44, 45, and 47]. OSCC raises the level of miRNAs. A reduction in apoptosis has been linked to increased production of miR-21, which targets tropomyosin 1 (TPM1) and PTEN [44, 45, 48]. Similarly, downregulation of CDKN1B, a downstream target of DND1, promotes multiplication, whereas overexpression of miR-24 suppresses apoptosis by lowering RNA-restricting protein impasse 1 (DND1) [44, 45, 49]. MiR-31 overexpression inhibits the articulation of factor-inducible factor (FIH). MiR-31 levels in OSCC patients' blood are higher than in healthy people [44, 45, 48, and 49]. Topoisomerase II (TOP2B), a TOP2 inhibitor, and high-portability gathering box A2 (HMGA2), a cisplatin and doxorubicin resistance enhancer, are likewise inhibited by overexpression of miR-23a and miR-98 [44, 45, 50, 51].

10-Downregulation of miRNAs in OSCC

MiR-133a regulates cell proliferation and death by increasing the expression of pyruvate kinase type M2 (PKM2) and glutathione-S-transferase P1 (GSTP1) [44, 45, 52, and 53]. Rho-related GTP-official protein C (RhoC) and Rho-related, looping curl containing protein kinase 2 (ROCK2) are targets of low miR-138 expression, which prevents metastasis [44, 45,53]. Downregulation of MiR-15a in OSCC inhibits PKC and cyclin E articulation, jeopardizing DNA union [44, 45, 53]. MiR-7 and miR-124, which target IGF1 and integrin beta-1 (ITGB1), respectively, exhibited reduced articulation in OSCC [45, 55, 10 and 57].

The majority of people will not get an oral tumor over their lives. Late information, on the other hand, can help identify the subset of persons who are more likely to develop oral cancer. Furthermore, improved screening tools and treatment options are now available, which may reduce the risk for these patients. Each major disclosure in science should be evaluated and verified by others. We arrive to the shocking conclusion that biomarkers in oral tumors are unimportant. This information suggests a function in disease progression biomarker development as well as a feasible target treatment for oral cancers. The findings of this investigation will be scrutinized by a large number of people. In the evaluations, the concern of mouth cancer growth was mentioned.

1. Argiris A, Karamouzis MV, Raben D, Ferris RL.Head and neck cancer. Lancet, 2008; 371: 1695-1709.
2. Bouquot JE. Common oral lesions found during a mass screening examination. J Am Dent Assoc., 1986; 112: 50-57.
3. Johnson N. Tobacco use and oral cancer: a global perspective. J Dent Educ., 2001; 65: 328-339.
4. 4-Horowitz AM, Goodman HS, Yellowitz JA, Nourjah PA. The need for health promotion in oral cancer prevention and early detection. J Public Health Dent., 1996; 56: 319-330.
5. Greene FL, Page DL, Fleming ID. AJCC Cancer Staging Manual. 6th ed. New York, NY: Head and neck sites. In: Springer-Verlag; 2002:17-87
6. National Cancer Institute. Oral complications of chemotherapy and head/neck radiation. Health Professional Version. Available from NCI, 2008.
7. Electronic Medicines Compendium (UK).
8. Birnbaum W, Dunne SM. Oral diagnosis: the clinician’s guide. Wright, Oxford, 2000.
9. Scully C, Felix DH. Oral medicine-update for dental practitioner. Aphthous and other common ulcers. Br Dent J, 2005; 199: 259-264.
10. Hunt S, Jones AV, Hinsley EE, Whawell SA, Lambert DW. MicroRNA-124 suppresses oral squamous cell carcinoma motility by targeting ITGB1. FEBS Lett, 2011; 585: 187-192.
11. Pitiyage G, Tilakaratne WM, Tavassoli M, Warnakulasuriya S. Molecular markers in oral epithelial dysplasia: review. J Oral Pathol Med, 2009; 38: 737-752.
12. Choi S, Myers JN. Molecular pathogenesis of oral squamous Cell carcinoma: implications for therapy. J Dental Res, 2008; 87: 14-32
13. Reuter CW, Morgan MA, Eckardt A. Targeting EGF receptor signaling in squamous cell carcinomas of the head and neck. Br J Cancer, 2007; 96: 408-416.
14. Cavalot A, Martone T, Roggero N, Brondino G, Pagano M, Cortesina G. Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas. Head Neck, 2007; 9: 655-664.
15. Grimminger CM, Danenberg PV. Update of prognostic and predictive biomarkers in oropharyngeal squamous cell carcinoma: a review. Eur Arch Oto-Rhino-Laryngol, 2011; 268: 5-16
16. Sun XF, Zhang H. NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol Histopathol, 2007; 22:1387-1398
17. Yan M, Xu Q, Zhang P, Zhou XJ, Zhang ZY, Chen WT. Correlation of NF-kappaB signal pathway with tumor metastasis of human head and neck squamous cell carcinoma. BMC Cancer, 2010;10: 437.
18. Furuta H, Osawa K, Shin M, Ishikawa A, Matsuo K, Khan M, Aoki K, Ohya K, Okamoto M, Tominaga K, Takahashi T, Nakanishi O, Jimi E, et al. Selective inhibition of NF-kappaB suppresses bone invasion by oral squamous cell carcinoma in vivo.Int J Cancer, 2012; 131: E625-E635.
19. Watari K, Nakamura M, Fukunaga Y, Furuno A, Shibata T, Kawahara A, Hosoi F, Kuwano T, Kuwano M, Ono M, et al. The antitumor effect of a novel angiogenesis inhibitor (an octahydronaphthalene derivative) targeting both VEGF receptor and NF-kappaB pathway. Int J Cancer, 2012; 131: 310-321.
20. Tamatani T, Azuma M, Ashida Y, Motegi K, Takashima R, Harada K, Kawaguchi S, Sato M, et al. Enhanced radiosensitization and chemosensitization in NF-kappaB-suppressed human oral cancer cells via the inhibition of gamma-irradiation- and 5-FU-induced production of IL-6 and IL-8. Int J Cancer, 2004; 108:912-921.
21. Bussink J, van der Kogel AJ, Kaanders JH. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol, 2008; 9: 288-296.
22. Murugan AK, Hong NT, Fukui Y, Munirajan AK, Tsuchida N. Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas. Int J Oncol, 2008; 32:101-111
23. Macha MA, Matta A, Kaur J, Chauhan SS, Thakar A, Shukla NK, Gupta SD, Ralhan R. Prognostic significance of nuclear pSTAT3 in oral cancer. Head Neck, 2011; 33:482-489.
24. Yu Z, Weinberger PM, Haffty BG, Sasaki C, Zerillo C, Joe J, Kowalski D, Dziura J, Camp RL, Rimm DL, Psyrri A, et al. Cyclin d1 is a valuable prognostic marker in oropharyngeal squamous cell carcinoma. Clin Cancer Res, 2005; 11:1160-1166
25. Miyamoto R, Uzawa N, Nagaoka S, Hirata Y, Amagasa T. Prognostic significance of cyclin D1 amplifi cation and overexpression in oral squamous cell carcinomas. Oral Oncol, 2003; 39:610-618
26. Wang L, Liu T, Nishioka M, Aguirre RL, Win SS, Okada N. Activation of ERK1/2 and cyclin D1 expression in oral tongue squamous cell carcinomas: relationship between clinicopathological appearances and cell proliferation. Oral Oncol, 2006; 42: 625-631.
27. Zhou X, Zhang Z, Yang X, Chen W, Zhang P. Inhibition of cyclin D1 expression by cyclin D1 shRNAs in human oral squamous cell carcinoma cells is associated with increased cisplatin chemosensitivity. Int J Cancer, 2009;124: 483-489.
28. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer, 2009; 9:798-809.
29. Adachi M, Cui C, Dodge CT, Bhayani MK, Lai SY. Targeting STAT3 inhibits growth and enhances radiosensitivity in head and neck squamous cell carcinoma. Oral Oncol, 2012;48:1220-1226.
30. Klosek SK, Nakashiro K, Hara S, Li C, Shintani S, Hamakawa H. Constitutive activation of Stat3 correlates with increased expression of the c-Met/HGF receptor in oral squamous cell carcinoma. Oncol Rep, 2004; 12: 293-296
31. Nagpal JK, Patnaik S, Das BR. Prevalence of high-risk human papilloma virus types and its association with P53 codon 72 polymorphism in tobacco addicted oral squamous cell carcinoma (OSCC) patients of Eastern India. Int J Cancer, 2002; 97: 649-653
32. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000; 408: 307-310.
33. Shiraishi K, Kato S, Han SY, Liu W, Otsuka K, Sakayori M, IshidaT, Takeda M, Kanamaru R, Ohuchi N, Ishioka C, et al. Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library. J Biol Chem, 2004; 279: 348-355.
34. Ries JC, Schreiner D, Steininger H, Girod SC. p53 mutation and detection of p53 protein expression in oral leukoplakia and oral squamous cell carcinoma. Anticancer Res, 1998; 18: 2031-2036
35. Leemans CR, Braakhuis BJ, Brakenhoff RH. the molecular Biology of head and neck cancer. Nat Rev Cancer, 2011; 11: 9-22.
36. Kato K, Kawashiri S, Yoshizawa K, Kitahara H, Yamamoto E. Apoptosis-associated markers and clinical outcome in human oral squamous cell carcinomas. J Oral Pathol Med, 2008; 37: 364-371.
37. Bauer JA, Trask DK, Kumar B, Los G, Castro J, Lee JS, Chen J, Wang S, Bradford CR, Carey TE, et al. Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL. Mol Cancer Therap, 2005; 4:1096-1104.
38. Staibano S, Mignogna MD, Lo Muzio L, Di Alberti L, Di Natale E, Lucariello A, Mezza E, Bucci E, DeRosa G. Overexpression of cyclin-D1, bcl-2, and bax proteins, proliferating cell nuclear antigen (PCNA), and DNA-ploidy in squamous cell carcinoma of the oral cavity. Hum Pathol, 1998; 29:1189-1194
39. Xie X, Clausen OP, Boysen M. Prognostic value of Bak expression in oral tongue squamous cell carcinomas. Oncol Rep, 2003; 10: 369-374
40. Camisasca DR, Honorato J, Bernardo V, da Silva LE, da Fonseca EC,de Faria PA, Dias FL, Lourenco Sde Q, et al. Expression of Bcl-2 family proteins and associated clinicopathologic factors predict survival outcome in patients with oral squamous cell carcinoma. Oral Oncol, 2009; 45: 225-233.
41. Sasabe E, Tatemoto Y, Li D, Yamamoto T, Osaki T. Mechanism of HIF-1alpha-dependent suppression of hypoxiainduced apoptosis in squamous cell carcinoma cells. Cancer Sci, 2005; 96: 394-402.
42. Melo SA, Kalluri R. Molecular pathways: microRNAs as cancer therapeutics. Clin Cancer Res, 2012; 18: 4234-4239.
43. Chen CZ. MicroRNAs as oncogenes and tumor suppressors. New Engl J Med, 2005; 353:1768-1771.
44. Wu BH, Xiong XP, Jia J, Zhang WF. MicroRNAs: new actors in the oral cancer scene. Oral Oncol, 2011; 47: 314-319.
45. Perez-Sayans M, Pilar GD, Barros-Angueira F, Suarez-Penaranda JM, Fernandez AC, Gandara-Rey JM, Garcia-Garcia A, et al. Current trends in miRNAs and their relationship with oral squamous cell carcinoma. J Oral Pathol Med, 2012; 41: 433-443.
46. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK. Dicer, Drosha, and outcomes in patients with ovarian cancer. New Engl J Med, 2008; 359: 2641-2650.
47. Liu X, Yu J, Jiang L, Wang A, Shi F, Ye H, Zhou X. MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1 (MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines. Cancer Genomics Proteomics, 2009; 6: 131-39
48. Li J, Huang H, Sun L, Yang M, Pan C, Chen W, Wu D, Lin Z, Zeng C, Yao Y, Zhang P, Song E. MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res, 2009; 15: 3998-4008.
49. Liu CJ, Tsai MM, Hung PS, Kao SY, Liu TY, Wu KJ, Chiou SH, Lin SC, Chang KW. miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. Cancer Res, 2010; 70: 1635-1644.
50. Liu X, Wang A, Heidbreder CE, Jiang L, Yu J, Kolokythas A, Huang L, Dai Y, Zhou X. MicroRNA-24 targeting RNA binding protein DND1 in tongue squamous cell carcinoma. FEBS Lett, 2010; 584: 4115-4120.
51. Liu CJ, Kao SY, Tu HF, Tsai MM, Chang KW, Lin SC. Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. Oral Dis, 2010; 16: 360-364.
52. Yu ZW, Zhong LP, Ji T, Zhang P, Chen WT, Zhang CP. MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol, 2010; 46: 317-322.
53. Hebert C, Norris K, Scheper MA, Nikitakis N, Sauk JJ. High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer, 2007; 6: 5.
54. Wong TS, Liu XB, Chung-Wai Ho A, Po-Wing Yuen A, Wai-Man Ng R, Ignace Wei W. Identifi cation of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profi ling. Int J Cancer, 2008; 123: 251-257.
55. Mutallip M, Nohata N, Hanazawa T, Kikkawa N, Horiguchi S, Fujimura L, Kawakami K, Chiyomaru T, Enokida H, Nakagawa M, Okamoto Y, Seki N. Glutathione S-transferase P1(GSTP1) suppresses cell apoptosis and its regulation by miR-133alpha in head and neck squamous cell carcinoma (HNSCC). Int J Mol Med, 2011; 27: 345-352.
56. Chang KW, Liu CJ, Chu TH, Cheng HW, Hung PS, Hu WY, Lin SC. Association between high miR-211 microRNA expression and the poor prognosis of oral carcinoma. J Dental Res, 2008; 87: 1063-1068
57. Jiang L, Liu X, Chen Z, Jin Y, Heidbreder CE, Kolokythas A,Wang A, Dai Y, Zhou X. MicroRNA-7 targets IGF1R (insulin- like growth factor 1 receptor) in tongue squamous cell carcinoma cells. Biochem J, 2010; 432: 199-205.